Tie2 expression on macrophages is required for blood vessel reconstruction and tumor relapse after chemotherapy

Cancer Research

Volumn 76, Issue 23, 2016, Pages 6828-6838

  Chen, Lin ^a,b   Li, Jie ^a,b   Wang, Fei ^a   Dai, Chengliang ^b   Wu, Fan ^b   Liu, Xiaoman ^b   Li, Taotao ^c   Glauben, Rainer ^d   Zhang, Yi ^a   Nie, Guangjun ^e   He, Yulong ^c   Qin, Zhihai ^a,b  

^a ZHENGZHOU UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; IN VIVO STUDY; LIMIT OF QUANTITATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; VASCULAR SURGERY; VASCULARIZATION; ANIMAL; BLOOD; C57BL MOUSE; GENETIC TRANSFECTION; HUMAN; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY);

ANIMALS; HUMANS; MACROPHAGES; MICE; MICE, INBRED C57BL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 85002801826     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-1114     Document Type: Article

References (50)

1. Chabner BA, Longo DL. Cancer chemotherapy and biotherapy: principles and practice. Philadelphia: Lippincott Williams & Wilkins; 2011.
2. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-92.
3. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72.
4. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012;18:1359-68.
5. Schrader J, Gordon-Walker TT, Aucott RL, van Deemter M, Quaas A, Walsh S, et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology 2011;53:1192-205.
6. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006;116:1955-62.
7. Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005;19:26-31.
8. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T. Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med 2001;194:1549-59.
9. De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013;23:277-86.
10. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
11. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011;19:512-26.
12. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994;8:1897-909.
13. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010;10:575-85.
14. Pfizer. Safety and PK study of CVX-060 in patients with advanced solid tumors. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2011- [cited 2014 Sep 1]. Available from: http://clinicaltrials.gov/ct2/show/NCT00879684?term=ang2&rank=7. NLM Identifier: NCT00879684.
15. Pfizer. PF-04856884 (CVX-060) in combination with axitinib in patients with previously treated metastatic renal cell carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2014- [cited 2014 Sep 1]. Available from: http://clinicaltrials.gov/ct2/show/NCT01441414?term=ang2&rank=3. NLM Identifier: NCT01441414.
16. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26.
17. De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003;9:789-95.
18. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010;120:694-705.
19. Patel AS, Smith A, Nucera S, Biziato D, Saha P, Attia RQ, et al. TIE2-expressing monocytes/macrophages regulate revascularization of the ischemic limb. EMBO Mol Med 2013;5:858-69.
20. Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010;70:5270-80.
21. Murdoch C, Tazzyman S, Webster S, Lewis CE. Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 2007;178:7405-11.
22. Coffelt SB, Chen YY, Muthana M, Welford AF, Tal AO, Scholz A, et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J Immunol 2011;186:4183-90.
23. Thomas M, Felcht M, Kruse K, Kretschmer S, Deppermann C, Biesdorf A, et al. Angiopoietin-2 stimulation of endothelial cells induces alphavbeta3 integrin internalization and degradation. J Biol Chem 2010;285:23842-9.
24. Bezuidenhout L, Zilla P, Davies N. Association of Ang-2 with integrin beta 2 controls Ang-2/PDGF-BB-dependent upregulation of human peripheral blood monocyte fibrinolysis. Inflammation 2009;32:393-401.
25. Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu J, et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest 2012;122:1991-2005.
26. Scholz A, Lang V, Henschler R, Czabanka M, Vajkoczy P, Chavakis E, et al. Angiopoietin-2 promotes myeloid cell infiltration in a beta(2)-integrin-dependent manner. Blood 2011;118:5050-9.
27. Shen B, Shang Z, Wang B, Zhang L, Zhou F, Li T, et al. Genetic dissection of tie pathway in mouse lymphatic maturation and valve development. Arterioscler Thromb Vasc Biol 2014;34:1221-30.
28. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003;63:4095-100.
29. Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T, et al. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 2008;10:513-26.
30. Zhang J, Chen L, Xiao M, Wang C, Qin Z. FSP1+ fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflammation. Am J Pathol 2011;178:382-90.
31. Chen L, Li J, Zhang J, Dai C, Liu X, Wang J, et al. S100A4 promotes liver fibrosis via activation of hepatic stellate cells. J Hepatol 2015;62:156-64.
32. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99:1441-54.
33. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005;97:512-23.
34. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 1999;8:265-77.
35. Fantin A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhozhij S, et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 2010;116:829-40.
36. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
37. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013;13:739-52.
38. Piret JP, Mottet D, Raes M, Michiels C. CoCl2, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. Ann N Y Acad Sci 2002;973:443-7.
39. Kim JY, Kim YJ, Lee S, Park JH. The critical role of ERK in death resistance and invasiveness of hypoxia-selected glioblastoma cells. BMC Cancer 2009;9:27.
40. Hou M, Cui J, Liu J, Liu F, Jiang R, Liu K, et al. Angiopoietin-like 4 confers resistance to hypoxia/serum deprivation-induced apoptosis through PI3K/Akt and ERK1/2 signaling pathways in mesenchymal stem cells. PLoS One 2014;9:e85808.
41. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003;63:4441-9.
42. Vidal S, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2014;33:4451-63.
43. Daenen LG, Houthuijzen JM, Cirkel GA, Roodhart JM, Shaked Y, Voest EE. Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies. Oncogene 2014;33:1341-7.
44. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008;9:628-38.
45. Hughes R, Qian B-Z, Rowan C, Muthana M, Keklikoglou I, Olson OC, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res 2015;75:3479-91.
46. Cooney MM, van Heeckeren W, Bhakta S, Ortiz J, Remick SC. Drug Insight: vascular disrupting agents and angiogenesis[mdash]novel approaches for drug delivery. Nat Clin Prac Oncol 2006;3:682-92.
47. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc 2000;5:40-6.
48. Liu C, Wu C, Yang Q, Gao J, Li L, Yang D, et al. Macrophages mediate the repair of brain vascular rupture through direct physical adhesion and mechanical traction. Immunity 2016;44:1162-76.
49. Cao Y, Eble JM, Moon E, Yuan H, Weitzel DH, Landon CD, et al. Tumor cells upregulate normoxic HIF-1alpha in response to doxorubicin. Cancer Res 2013;73:6230-42.
50. De Palma M, Lewis CE. Cancer: macrophages limit chemotherapy. Nature 2011;472:303-4.